A patent is, at bottom, a 20-year permission slip to sue people. The Patent Act gives the owner the right to exclude others from making, using, selling, offering to sell, or importing the claimed invention (35 U.S.C. § 154; 35 U.S.C. § 271)—and nothing more. It does not give the owner a single customer, a factory, a sales force, or a dollar of revenue. Many inventors discover this the hard way, framing the issued patent on the wall and waiting for the world to beat a path to their door. The world rarely shows up.

Licensing is how you convert that right to exclude into cash. Instead of building the factory and fighting for market share, you grant someone else permission to do those things, and you take a cut. Done well, a license creates value that neither party could capture alone: the licensor earns revenue without sinking capital into manufacturing, and the licensee gets access to protected technology without years of independent development—and, often, peace of mind that it will not be sued. Done poorly, a license gives away the crown jewels for a pittance, traps you in a contract with a partner who sits on your invention, or—because of a line of Supreme Court cases most inventors have never heard of—silently makes a chunk of your royalty stream legally uncollectible.

This guide runs the whole arc, and it does so by following a hypothetical to keep the abstractions honest. Meet Helix Materials, a (made-up) materials-science startup that holds a strong patent on a durable anti-corrosion coating. Helix has a brilliant invention and roughly none of what it would take to commercialize it: no industrial-scale coating line, no distribution into the marine and pipeline markets where the coating shines, no capital to build either. Helix's choices—whether to license at all, what the patent is worth, whom to approach, how to structure the grant, how to design the royalties, and how to paper the deal—are the choices every licensor faces. We will walk them in order.

A note before we start: a patent license is one move in a larger intellectual-property strategy. The same diligence that tells a licensee whether it is safe to sell a product—a freedom-to-operate analysis—tells a licensor how badly a given company needs its license. The same doctrines that govern an infringement suit—what a claim covers, what defenses exist—set the backstop against which every license is negotiated, as our guide to patent infringement claims and defenses explains. And the raw material of any license is a well-prepared patent, which starts with a good invention disclosure to your patent attorney. Keep those three in your peripheral vision throughout.

Should You License at All? The Threshold Assessment

Not every patent is a good licensing candidate, and the most expensive mistake in the field is spending six months and a chunk of legal budget pitching a patent nobody wants. Before valuation and outreach, run an honest threshold assessment. Four questions do most of the work.

Commercial relevance. Does the patent cover technology companies actually want to use? Patents issue every day on inventions that are genuinely novel and non-obvious and also commercially pointless—they solve a problem no one has, or a problem that a cheaper alternative solved last year. The patent examiner asks whether the invention is new; the market asks whether anyone will pay for it. Those are different questions, and only the second one generates royalties. Start with market analysis: who participates in the relevant market, what they use today, and why your technology beats it.

Claim scope. A patent protects exactly what its claims cover and not one atom more, so the claims—not the glossy description in the specification—define what actually requires a license. Broad claims that capture a fundamental aspect of a technology are worth far more than narrow claims a competitor can sidestep with a trivial redesign. Read your claims with a skeptic's eye, ideally a skeptic who designs products for a living and will tell you how he would engineer around them. Claim-scope analysis is the same discipline that drives freedom-to-operate work: the question "what does this patent really cover?" is identical whether you are the one wielding it or the one worried about it.

Patent strength. A patent likely to survive a validity challenge commands higher royalties than one with a glaring prior-art problem, because a licensee is really paying to make a lawsuit go away, and a weak patent is a cheap lawsuit. The prosecution history matters here in two directions: narrowing amendments and arguments made to get the patent allowed both limit the doctrine of equivalents and hand a future challenger ammunition. A clean file history is an asset you can charge for.

Remaining term. Patents generally expire 20 years from the earliest effective filing date (35 U.S.C. § 154), and—this is the part licensors forget—a royalty stream cannot legally outlive the patent (more on Brulotte and Kimble below). A patent with 15 years left is worth far more than one with three, and a patent that lapsed last quarter because someone missed a maintenance fee is worth nothing. Confirm term and maintenance-fee status through the USPTO's Patent Center before you do anything else.

Helix's coating patent scores well across the board: broad claims that capture the core chemistry, roughly twelve years of remaining term, a clean prosecution history, and a market—offshore equipment and pipeline operators who lose fortunes to corrosion—that is desperate for exactly this. The assessment tells Helix the effort is worth making. For a patent that scored poorly on three of four, the right answer might be to abandon it and stop paying maintenance fees.

Valuation: What Is Your Patent Worth?

Patent valuation is famously hard. A patent is a one-of-a-kind legal instrument whose value depends on the technology, the markets it touches, its enforceability, and the specific parties at the table—and most of those inputs are uncertain. No single method is definitive. But three classic approaches, used together, bound the range and give you something defensible to anchor a negotiation. Think of them as three witnesses to the same event, each unreliable alone, more trustworthy in agreement.

The cost approach asks what it would cost to recreate or design around the technology. If a licensee could independently develop a comparable coating for $5 million over two years, then a license priced below that—and available now—is attractive, because the licensee saves the money and, more importantly, the two years. The cost approach sets a useful ceiling from the licensee's perspective (no rational licensee pays more than its design-around cost) but says almost nothing about the floor, and it ignores how much money the technology will actually make. It is the bluntest of the three.

The market approach values the patent against comparable transactions—what have similar patents licensed for? This is the approach a real-estate appraiser would recognize, and it suffers from the same weakness: truly comparable "comps" are scarce. Patents differ in scope, term, field, and exclusivity; license agreements differ in structure, bundled know-how, and the parties' relative leverage. Royalty-rate databases (ktMINE, RoyaltySource) and surveys from organizations like the Licensing Executives Society (LES) supply data points, but each requires subjective adjustment to fit your facts. Courts share the skepticism: a damages analysis built on supposedly comparable licenses must actually be comparable in technology and economic circumstance, or it gets thrown out (ResQNet.com, Inc. v. Lansa, Inc., 594 F.3d 860, 869–72 (Fed. Cir. 2010)).

The income approach values the patent on the future income it is expected to generate, discounted to present value. It is the most conceptually sound of the three and the most assumption-hungry—you must estimate licensee revenue, the royalty rate, the duration, and a discount rate, and small changes in any of them swing the answer wildly. For licensing, the income approach has an intuitive translation: a rational licensee pays for a license only if the expected benefit exceeds the cost, so the patent is worth some share of the extra profit the licensee earns because it has the technology rather than the next-best alternative.

That "share of the profit" framing is where the famous 25 percent rule came from—the rough heuristic that a reasonable royalty might be a quarter of the licensee's expected profit attributable to the patented feature. It is worth knowing the rule and worth knowing it is dead as a matter of litigation. In Uniloc USA, Inc. v. Microsoft Corp., 632 F.3d 1292, 1315 (Fed. Cir. 2011), the Federal Circuit held the 25 percent rule "a fundamentally flawed tool" inadmissible as a starting point for a damages opinion, precisely because it bears no relation to the specific facts of the case. It survives only as a back-of-the-envelope sanity check on intuition, never as evidence. A licensor who builds a number on the 25 percent rule and nothing else has built a number a court will not credit and a sophisticated counterparty will laugh at.

In practice, valuation triangulates: the cost approach caps the price, the market approach supplies comparables, and the income approach models the upside, and the three together yield a range. For Helix, the analysis produces something like "a $250,000–$750,000 upfront against a 4%–7% running royalty on net sales, depending on exclusivity and field"—a defensible band, not a single magic number. That band is the point. You do not walk into a negotiation with a number; you walk in with a range and the reasoning behind it.

A Word on the Georgia-Pacific Factors—Even If You Never Litigate

Here is the most useful thing a licensor can borrow from litigation: the Georgia-Pacific framework. When a court has to set a "reasonable royalty"—the statutory floor for infringement damages, "in no event less than a reasonable royalty for the use made of the invention by the infringer" (35 U.S.C. § 284)—it runs a thought experiment. It imagines a hypothetical negotiation between a willing licensor and a willing licensee, conducted just before infringement began, on the assumption that the patent is valid and infringed (Lucent Techs., Inc. v. Gateway, Inc., 580 F.3d 1301, 1324–25 (Fed. Cir. 2009)). To structure that imagined bargain, courts use the fifteen factors from Georgia-Pacific Corp. v. U.S. Plywood Corp., 318 F. Supp. 1116, 1120 (S.D.N.Y. 1970), modified, 446 F.2d 295 (2d Cir. 1971).

Why should a licensor who never plans to sue care? Because the hypothetical negotiation is your negotiation. The factors that a court uses to reconstruct a fair royalty are the same factors that determine a fair royalty across a conference table. Run through them and you have a negotiation checklist disguised as a damages framework. The fifteen, grouped sensibly:

  • What the rate should be (licensing factors): royalties the patentee has actually received that establish a going rate (factor 1); rates the licensee pays for comparable patents (factor 2); and the established royalty for the technology, if one exists.
  • Business and relationship factors: the nature and scope of the license—exclusive or not, restricted or not (factor 3); the licensor's established licensing policy (factor 4); the commercial relationship between the parties, including whether they compete (factor 5); the convoyed-sales value of the patent as a driver of sales of other, unpatented products (factor 6); the patent's remaining duration and the license term (factor 7); and the established profitability and commercial success of products made under the patent (factor 8).
  • Value-of-the-invention factors: the utility and advantages of the patented technology over the old way of doing things (factor 9); the nature and benefits of the invention to those who use it (factor 10); the extent of the infringer's use and evidence of its value (factor 11); and the customary profit allowed for use of the invention in the trade (factor 12).
  • The apportionment factor and the overall bargain: the portion of the realizable profit creditable to the patented invention as distinguished from non-patented elements, business risk, and features the infringer added (factor 13); expert opinion (factor 14); and the bottom-line hypothetical negotiation itself (factor 15).

Factor 13 deserves a star, because it is the doctrine that has eaten patent damages over the last fifteen years and quietly governs every license on a multi-component product.

Apportionment: The Royalty Base Is Half the Deal

The royalty rate gets all the attention, but the royalty base—the number the rate multiplies—is at least as important and far more dangerous. A 5% royalty on a $10 sensor chip and a 5% royalty on the $40,000 machine the chip sits inside are the same rate and wildly different deals.

The law's answer is apportionment: a royalty must be tied to "the claimed invention's footprint in the marketplace" and may not capture value attributable to unpatented features (Finjan, Inc. v. Blue Coat Sys., Inc., 879 F.3d 1299, 1309–10 (Fed. Cir. 2018); Ericsson, Inc. v. D-Link Sys., Inc., 773 F.3d 1201, 1232–33 (Fed. Cir. 2014)). A patentee is limited to "only those damages attributable to the infringing features" (VirnetX, Inc. v. Cisco Sys., Inc., 767 F.3d 1308, 1326 (Fed. Cir. 2014)). For a multi-component product, you generally cannot use the entire market value of the whole product as the base unless the patented feature is what drives consumer demand for the entire product—a stringent test that courts rarely find satisfied. The safer move is to build the base on the smallest salable patent-practicing unit (the smallest component that embodies the invention) and then apportion further within even that unit if it bundles patented and unpatented value (LaserDynamics, Inc. v. Quanta Computer, Inc., 694 F.3d 51, 67–70 (Fed. Cir. 2012); Commonwealth Sci. & Indus. Research Org. v. Cisco Sys., Inc., 809 F.3d 1295, 1302–03 (Fed. Cir. 2015)).

Why does litigation doctrine matter to a deal that may never see a courtroom? Because the base you negotiate must be defensible if it ever does, and because a base that overreaches invites a challenge. This is a live concern for Helix, whose coating is applied to products—pipes, hulls, valves—that Helix does not make and that are worth orders of magnitude more than the coating. A naïve term sheet that pegs the royalty to "net sales of the coated product" would set the base at the value of an entire offshore valve assembly, most of which has nothing to do with Helix's chemistry. A defensible base ties the royalty to the value of the coating itself: a per-square-meter rate, a percentage of the price of the coating as sold, or a rate on the smallest unit that fairly captures the invention's contribution. Get this wrong and you have either left money on the table or built a royalty a licensee can later attack as unapportioned and unenforceable. Our guide to infringement claims and defenses walks through how these damages doctrines play out in litigation; in licensing, they set the gravity that every base definition has to fight.

Identifying the Right Licensees

With a valuation range in hand, you need a target list—entities that would benefit from the technology and can pay for it. Several pools are worth canvassing.

Competitors in the patent's space are the obvious candidates. Companies already making products that arguably read on your claims face real risk and have an obvious reason to license. Find them through competitive intelligence, trade publications, and patent searches—and through your own patent's forward citations, because a company that cited your patent as prior art during its own prosecution has, in writing, told the world it knows about your technology.

Companies that could benefit but are not yet using the technology are the expansion play. They are harder to find—you are looking for an unmet need, not an existing product—but a non-competitor who slots your technology into a new application can be a more cooperative and durable partner than a rival you are effectively forcing to the table.

Entities already implementing without authorization are the most fraught category. They are infringers, and they are also the most likely to deny infringement, challenge your patent's validity, and turn a licensing pitch into a litigation threat. Many sophisticated licensors build a program with willing licensees first—accumulating a roster of paying partners that establishes a going royalty rate (a Georgia-Pacific factor-1 fact)—before turning to the holdouts. A patent licensed by five willing companies at 5% is a far more intimidating thing to a holdout than a patent licensed by no one. Approach known infringers with care, and with counsel: an aggressive demand letter can trigger a declaratory-judgment suit in a forum not of your choosing (MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007), opened that door wider than many realize).

Universities and research institutions can be licensees, referral sources, or both; research use sometimes falls within narrow safe harbors, so a research-only license is a different animal from a commercial one.

And remember that geography defines the universe. Patent rights are territorial. A U.S. patent stops nothing abroad. If Helix holds only U.S. rights, its targets are companies that make, use, or sell in the United States; if it has secured foreign counterparts, the worldwide market opens up and multinational manufacturers become viable partners. The territorial reach you actually own is the territorial reach you can sell.

Licensing Structures: Exclusive, Non-Exclusive, and the Spectrum Between

The single most consequential structural choice is exclusive versus non-exclusive, and it is really a choice between depth and breadth.

An exclusive license grants the sole right to practice the patent—typically excluding even the licensor, unless the licensor reserves rights. Exclusivity gives the licensee a protected position, which justifies the heavy investment commercialization often requires, and so it commands premium royalties or a substantial upfront. It is the natural structure when one capable partner will pour money into building a market and needs to know a competitor (or the licensor itself) cannot free-ride on that investment. The trade-off for the licensor is dependency: you have bet your patent on a single horse, and if that horse won't run, your revenue dies. Guard against the non-performing exclusive licensee with the three classic levers—performance milestones, minimum annual royalties, and termination rights—so that exclusivity is conditional on diligence, not a gift.

A non-exclusive license keeps the licensor free to license others, generating competition among licensees, lower per-deal royalties, and—the upside—reach and diversified revenue. It suits broadly applicable technologies where no single licensee needs to be the only player, and it is the default for standards and fundamental building-block technologies. Functionally, a non-exclusive license is a covenant not to sue: the licensor simply promises not to enforce the patent against the licensee's covered activities.

A third, often-overlooked option sits between them: the sole license, which grants exclusivity against all third parties but lets the licensor itself keep practicing the patent. A sole license is the right tool when the licensor is still doing research with the technology, or is already (or planning to be) commercializing it in a way that complements rather than competes with the licensee. "Exclusive," "sole," and "non-exclusive" are three distinct grants, and using the wrong word in a term sheet creates exactly the ambiguity that breeds disputes.

Between the poles lie the hybrids, and this is where a clever licensor multiplies value:

  • Field-of-use restrictions grant exclusivity within defined applications. Helix might license its coating exclusively for marine and offshore applications to a partner with offshore expertise, while licensing it non-exclusively for industrial piping to several others. One patent, several non-overlapping deals, each licensee matched to its strength. (One caution: if you carve fields finely, obligate each licensee not to operate outside its field, because a licensee that strays into another's field both breaches your structure and exposes you to a patent-misuse argument.)
  • Geographic restrictions divide rights by territory—exclusive North America to one partner, exclusive Europe to another.
  • Temporal restrictions grant initial exclusivity that converts to non-exclusive after a head-start period, giving an early licensee a runway while preserving the licensor's long-term flexibility.
  • Quantity limitations cap units, letting the licensor reserve capacity to serve demand the licensee cannot.

Each hybrid is a way of slicing the bundle of exclusionary rights into pieces and selling each piece to whoever values it most. For technologies that become essential to an industry standard, exclusivity gives way to an obligation to license everyone on fair terms—the FRAND regime we cover in standard-essential patents and FRAND licensing in 5G and IoT, and which we return to below.

Royalty Architecture: Designing the Payment Stream

Compensation structure is where the parties allocate risk, and the menu is richer than "what's the percentage?"

Running royalties—a percentage of covered sales, or a fixed amount per unit—tie the licensor's take to the licensee's success and keep both parties rowing in the same direction. Rates vary enormously by industry. As rough, confirm-before-relying ranges: software often 0.5%–5% of net sales; pharmaceuticals frequently 2%–15%, swinging with development stage and risk; manufacturing and materials technology often 1%–7%. These are starting points, not gospel—the right rate falls out of the Georgia-Pacific analysis applied to your facts, not out of a table.

The royalty base matters as much as the rate, for all the apportionment reasons above. Net sales is the usual base, but "net sales" is a defined term that does real work: it is typically gross revenues less a specified list of deductions (returns, allowances, certain taxes, freight, trade discounts). Every undefined deduction is a future fight. And for component technologies, a per-unit royalty or a base built on the smallest salable unit is often cleaner and more defensible than a percentage of a bundled product price.

Lump-sum payments give fixed compensation regardless of how the product sells, which eliminates reporting and auditing, provides immediate cash, and gives the licensee certainty about its total cost. The trade-off is that the licensor surrenders the upside: if the product becomes a runaway hit, the lump sum looks like a giveaway in hindsight; if it flops, the lump sum looks like a windfall. Lump sums suit patents of uncertain value, hard-to-track sales, or situations where the licensee will not tolerate ongoing reporting (Lucent, 580 F.3d at 1326–27, catalogs the trade-offs).

Milestone payments tie compensation to development or commercialization events—a payment on regulatory approval, on first commercial sale, on hitting a sales threshold. They are ubiquitous in pharmaceutical and biotech deals, where value accretes in big discontinuous jumps as a candidate clears each hurdle.

Minimum annual royalties guarantee a floor and do double duty: they protect the licensor's revenue and they function as a diligence requirement, because a licensee that must pay $200,000 a year whether or not it sells anything has a powerful incentive to actually sell something. In an exclusive license, minimums are close to mandatory—they are the antidote to the exclusive licensee who takes the technology off the market by sitting on it.

Most real deals combine these into a layered structure: an upfront payment (compensating the licensor for the deal and signaling licensee commitment), running royalties (sharing the upside), minimum annual guarantees (flooring the downside and enforcing diligence), and milestones (front-loading value at key events). The exact mix is a negotiated expression of how the parties feel about risk. And the plumbing matters: specify reporting cadence (quarterly or annual), report deadlines, currency and conversion for foreign sales, and interest on late payments. A royalty that is owed but unreportable is a royalty you will spend more collecting than it is worth.

Two Diligence Levers Worth Getting Right

For exclusive licenses especially, the licensor needs assurance the licensee will actually commercialize. The blunt instrument is a best-efforts (or "commercially reasonable efforts") clause. The problem with bare best-efforts language is that it means whatever a court later decides it means, which is to say it means a lawsuit. Far better to make diligence objective: pair or replace the efforts clause with a minimum royalty (deemed satisfaction of the diligence obligation if paid) or a written commercialization plan with dated milestones and resource commitments. Objective benchmarks convert a vague promise into a measurable obligation, and measurable obligations generate fewer disputes and cleaner termination rights.

The Doctrinal Landmines: Five Rules That Can Void Your Deal

This is the section most "how to license" guides skip, and it is the most important. Patent licensing is not pure freedom of contract. A handful of doctrines—some over a half-century old, all still good law—will override what the parties agreed to and, in some cases, make perfectly negotiated terms unenforceable. A licensor who does not know them will draft a royalty stream that evaporates.

1. No Royalties After the Patent Expires: Brulotte and Kimble

You cannot collect patent royalties for activity after the patent expires. Full stop. In Brulotte v. Thys Co., 379 U.S. 29, 32 (1964), the Supreme Court held that a patentee's attempt to charge royalties for the use of a patented invention after the patent's expiration is unlawful per se—the patent monopoly ends when the patent does, and a contract that projects royalties past that point is unenforceable as to the post-expiration period.

If you think Brulotte was a relic ripe for overruling, so did a lot of people—and the Supreme Court disagreed. In Kimble v. Marvel Entertainment, LLC, 576 U.S. 446 (2015), the Court, applying stare decisis, expressly declined to overrule Brulotte even while acknowledging its economic reasoning was shaky. (The patent at issue covered a toy that let a child shoot foam webbing from the palm like Spider-Man; the inventor's royalty deal with Marvel ran past the patent's expiration, and the Court told him the post-expiration payments were uncollectible.) Brulotte is the law, and it is the law on purpose.

The practical consequences are enormous, and the workarounds are precise:

  • A license can run for the life of the patent, and royalties stop at expiration. If your portfolio has several patents expiring on different dates, the royalty obligation can be tied to "the last to expire."
  • A lower, stepped-down royalty after expiration is permissible only if the post-expiration payment is attributable to something other than the expired patent—ongoing access to know-how, trade secrets, services, or other consideration that has independent value. The classic authority is Aronson v. Quick Point Pencil Co., 440 U.S. 257, 264–66 (1979), where the Supreme Court enforced a royalty that continued even though a patent never issued, because the payments were really for the disclosed idea and the head start, not for a patent monopoly. So Helix can perfectly well license its patent and its proprietary application process and quality know-how, with the agreement structured so a reduced royalty survives the patent's expiration as payment for the continuing know-how license—provided the agreement says so clearly and the know-how is real (see also Warner-Lambert Pharm. Co. v. John J. Reynolds, Inc., 178 F. Supp. 655, 665–66 (S.D.N.Y. 1959), aff'd, 280 F.2d 197 (2d Cir. 1960); Nova Chems., Inc. v. Sekisui Plastics Co., 579 F.3d 319, 328–29 (3d Cir. 2009)).
  • Hybrid licenses bundling a patent with trade secrets should separately state the patent and non-patent components, so that the non-patent royalty survives expiration on its own legitimate footing.

Get this wrong and the most valuable, longest-dated part of your royalty stream is uncollectible the day the patent lapses—and a licensee that knows the rule will simply stop paying.

2. A Licensee Can Attack the Patent It Licensed: Lear v. Adkins

Intuitively, a licensee who has agreed to pay you for a patent should be estopped from turning around and arguing the patent is invalid. The Supreme Court rejected that intuition. In Lear, Inc. v. Adkins, 395 U.S. 653, 670–71 (1969), the Court abolished the doctrine of licensee estoppel, holding that the public interest in purging invalid patents outweighs the contract-law instinct to hold a licensee to its bargain. A licensee may challenge the validity of the very patent it licensed.

And it gets sharper. Under MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118, 137 (2007), a licensee does not even have to breach or repudiate the license before suing for a declaratory judgment that the patent is invalid, unenforceable, or not infringed. It can keep paying royalties under protest, keep its license intact, and simultaneously litigate to blow up the patent. If it wins, it stops paying and keeps operating; if it loses, it carries on under the license as if nothing happened. Heads the licensee wins, tails the licensor doesn't lose much.

For licensors, Lear and MedImmune mean the validity of your patent is never truly settled by a license; a determined licensee can always reopen it. Drafters respond with what tools survive Lear—not no-challenge clauses (generally unenforceable), but provisions that raise the cost of a challenge: royalty step-ups during a challenge, fee-shifting for unsuccessful challenges, and termination rights triggered by a validity attack (so the licensee at least loses its license while it litigates). None of these can stop a challenge; they can make a licensee think twice. Our guide to patent infringement claims and defenses details the invalidity defenses a licensee-turned-challenger would actually raise.

3. Patent Exhaustion: One Authorized Sale Ends Your Rights in That Item

The doctrine of patent exhaustion (or "first sale") provides that an authorized sale of a patented article exhausts the patentee's rights in that article—the patentee cannot use patent law to control what the buyer does with it downstream. In Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008), the Supreme Court applied exhaustion to a licensed sale of components that substantially embodied the patented invention, cutting off LG's attempt to collect again downstream; later, Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 360 (2017), confirmed that exhaustion applies even to sales subject to contractual restrictions and even to foreign sales. The patent right is spent on first authorized sale; whatever restrictions you want on the buyer must live in contract, not patent law (and contract binds only your counterparty, not the world).

For a licensor, exhaustion shapes where in the supply chain to license and how to define the royalty event. If Helix licenses its coating to a component maker and that maker sells coated components, an authorized sale may exhaust the patent as to those components—so Helix cannot also collect from the downstream manufacturer who buys them. The fix is structural: license at the level where the value is, define the royalty-bearing event with exhaustion in mind, and use have-made rights deliberately (see below) rather than discovering exhaustion as a surprise. This is the same supply-chain reasoning a buyer runs in a freedom-to-operate analysis—from the other side of the table.

4. Patent Misuse: Overreaching Can Make Your Patent Unenforceable

Patent misuse is an equitable defense that renders a patent unenforceable—against everyone, until the misuse is purged—when the patentee impermissibly broadens the scope of the patent monopoly with anticompetitive effect. Classic misuse includes tying the license to the purchase of an unpatented product, requiring royalties on products that do not use the patent, and (per Brulotte) collecting post-expiration royalties. Congress narrowed the doctrine in 35 U.S.C. § 271(d), and the Supreme Court in Illinois Tool Works, Inc. v. Independent Ink, Inc., 547 U.S. 28 (2006), held that owning a patent no longer raises a presumption of market power for tying analysis. But misuse is alive, and it is a defense a licensee or infringer can raise, which means an overreaching license term can boomerang into unenforceability of the whole patent. Aggressive field restrictions, mandatory grant-backs, tie-ins, and total-sales royalties untethered to actual use are the usual suspects—structure them with antitrust counsel where the stakes warrant it.

5. Patent Marking: Mark, or Forfeit Past Damages

A quieter trap: under 35 U.S.C. § 287, if patented products are sold without marking them with the patent number (or "patent" plus a web address under virtual marking), the patentee cannot recover damages for infringement occurring before the infringer received actual notice—and a licensor is on the hook for its licensees' marking failures (Am. Med. Sys., Inc. v. Med. Eng'g Corp., 6 F.3d 1523, 1537–38 (Fed. Cir. 1993)). Every license that lets a licensee make products should require the licensee to mark, and give the licensor a right to verify compliance. Marking is unglamorous and routinely forgotten, and forgetting it can quietly erase years of recoverable damages.

The Other Deal Terms—Where Value Hides

Royalties get negotiated hard; the rest of the agreement gets skimmed, which is exactly backwards, because the non-royalty terms allocate the risks that actually blow up deals.

Grant of rights. Specify precisely which of the exclusionary rights pass—make, have made, use, sell, offer to sell, import—because each is severable. "Have made" rights (letting the licensee use contract manufacturers) deserve special attention: courts read a grant to "make, use, and sell" as including have-made rights by default, so a licensor who wants to withhold contract-manufacturing rights must say so expressly (CoreBrace LLC v. Star Seismic LLC, 566 F.3d 1069, 1074–75 (Fed. Cir. 2009)). The grant should also address which patents are covered and whether improvements, continuations, continuations-in-part, divisionals, reissues, and foreign counterparts come along.

Improvements and grant-backs. Who owns and who gets to use improvements made during the license term? A licensee usually wants access to the licensor's improvements; a licensor may want a grant-back of the licensee's improvements. Grant-backs are common and useful but carry antitrust freight—a broad, exclusive grant-back of a competitor's improvements can look like an attempt to corner a technology—so calibrate them (non-exclusive, field-limited) with the competition rules in mind.

Sublicensing. Decide whether the licensee can grant sublicenses (to distributors, manufacturing partners, affiliates), and on what terms. Licensors commonly require consent (not to be unreasonably withheld), and frequently take a cut of sublicense revenue. Silence on sublicensing is a gift to the licensee.

Most-favored-licensee (MFN) clauses. A licensee with leverage may demand an MFN: if the licensor later grants anyone better terms, the favored licensee gets them too. MFNs sound simple and create administrative headaches—they require comparing whole agreements, not just headline rates (a lower rate paired with a bigger upfront may or may not be "better"), and they can chill the licensor's ability to do creative later deals. Define carefully what counts as "more favorable" and what the remedy is.

Royalty stacking. If a licensee must take licenses from several patentees to ship one product, the royalties stack, and the licensee can end up paying more in total royalties than the product earns. Sophisticated licensees negotiate anti-stacking provisions—caps on aggregate royalty, or offsets that reduce your royalty if the licensee must pay others. Licensors resist; the resolution depends on leverage and on how crowded the patent thicket really is.

Audit rights. A running royalty is only as good as your ability to verify it. Reserve the right to audit the licensee's books, typically on reasonable notice, no more than once a year, at the licensor's expense—unless the audit turns up an underpayment over a threshold (commonly 5%), in which case the licensee pays for the audit and the shortfall, often with interest. Without an audit clause, "trust me" is your entire enforcement mechanism, and trust is not an accounting method.

Representations and warranties. A predictable tug-of-war. Licensors will represent that they own the patent and have authority to license it. They will resist—and usually expressly disclaim—any warranty of validity, enforceability, claim scope, or freedom to operate, because patents are presumptively but not actually unassailable, and no honest licensor can guarantee a court won't invalidate its patent or that practicing it won't infringe someone else's. A licensee with leverage may win knowledge-qualified or materiality-qualified versions of these reps; a smart licensee, regardless, runs its own freedom-to-operate analysis rather than relying on a warranty it probably won't get.

Indemnification. Two different risks travel under this heading, and conflating them causes grief. Infringement indemnity—covering claims that the licensed technology infringes a third party's patent—is something licensees want and licensors resist, because it asks the licensor to insure against a risk it cannot fully assess. Product-liability indemnity—covering claims that the licensee's product hurt someone—generally belongs on the licensee, which controls design, manufacturing, and quality. Caps, baskets, survival periods, and insurance requirements all get negotiated here.

Confidentiality. Technical know-how, royalty reports, and the deal's own financial terms all need protection, with careful attention to definitions, exceptions (information already public, independently developed, lawfully received from others), and survival. Where the license transmits real trade-secret know-how, the confidentiality regime is doing heavy lifting—see our guidance on building a trade secret protection program and on drafting enforceable NDAs for technology transactions.

Term, termination, and bankruptcy. Term usually runs for the life of the patent (subject to Brulotte). Termination triggers commonly include uncured material breach (after a cure period), failure to meet minimums or milestones, and bankruptcy. Bankruptcy deserves a clause of its own: a licensee that depends on the patent wants the comfort of Bankruptcy Code § 365(n), which lets a non-debtor licensee elect to retain its IP license rights even if a debtor-licensor's trustee rejects the contract—a protection worth invoking expressly.

Dispute resolution and governing law. Choose the forum—court, arbitration (AAA, JAMS, ICC), or mediation as a condition precedent—and the governing law, deliberately. Arbitration clauses in patent licenses raise their own wrinkles (arbitrability of validity, confidentiality of awards), and the choice should be made with eyes open, not copied from a form. Our overview of arbitration and choosing a dispute-resolution forum digs into the trade-offs.

Negotiation: Strategy and Leverage

Licensing negotiations are classic dealmaking with a few patent-specific twists.

Preparation is the whole game. Know your patent's strengths and its weaknesses (the other side's lawyers will find the weaknesses, so you had better find them first). Understand the licensee's business well enough to articulate why it needs your technology and what its next-best alternative is. Hold a defensible valuation range. And know your BATNA—your best alternative to a negotiated agreement—because the party that can credibly walk away holds the leverage. A licensor with three interested parties negotiates very differently from one with a single suitor.

Information asymmetry cuts both ways. The licensor knows more about prosecution history and validity; the licensee knows more about its commercial plans, margins, and risk tolerance. Managing what you disclose, and when, is strategic—an NDA up front lets both sides share enough to do a real deal without handing over the keys.

Anchoring matters. Behavioral research on negotiation is consistent: a credible, well-supported first offer pulls the final outcome toward it. Open aggressively but defensibly, with the reasoning attached. An anchor so extreme it lacks credibility doesn't anchor—it just signals that you're not serious and resets the other side's expectations downward.

Creative structures bridge genuine disagreement about facts. When the parties disagree about how the technology will perform, structure lets each bet on its own belief. If Helix is convinced its coating will dominate and a licensee is skeptical, a modest upfront plus a generous success-tied running royalty lets Helix capture the upside it believes in while protecting the licensee against the downside it fears. When the disagreement is about validity, escrowed or contingent payments can bridge it. The best deals often turn a dispute into a structure.

Know when to walk. If an offer fails your minimum requirements, or the term demands create unacceptable risk—an uncapped indemnity, a no-minimum exclusive, a base that invites a misuse defense—declining is the right answer, and genuine willingness to decline is itself leverage. A bad license can be worse than no license, because it ties up the patent and forecloses better partners.

The Term Sheet: Aligning Before You Draft

Before anyone drafts a forty-page definitive agreement, the parties usually capture their understanding in a term sheet (or letter of intent). A term sheet earns its keep by forcing clarity early—it surfaces the misalignment that would otherwise erupt at page thirty of the long-form draft, when both sides have spent real money. It gives counsel a roadmap and signals that the deal is serious.

Its binding nature requires care. Most term sheets are explicitly non-binding as to substantive terms, preserving each side's freedom to walk away—but certain provisions are typically meant to bind even in a non-binding term sheet: confidentiality, exclusivity during negotiations, the governing law of the term sheet itself, and allocation of negotiation costs. The cardinal rule is to say which provisions bind and which don't. Ambiguity here has produced expensive litigation over whether a "non-binding" term sheet was actually a contract.

A good patent-licensing term sheet identifies the licensed patents, describes the grant (exclusive/non-exclusive/sole, field, territory), states the financial terms (upfront, rate, base, minimums, milestones), addresses the key non-financial terms (sublicensing, term, termination, audit), sets a timeline for the definitive agreement, identifies which provisions bind, and states clearly that the rest do not.

A Sample Patent License Term Sheet, Annotated

What follows is a skeletal term sheet with annotations in brackets. It is a teaching tool, not a form to sign—every bracketed choice is a real decision that should be made with counsel for the specific deal.

PATENT LICENSE TERM SHEET

Date: [Current Date]

This term sheet summarizes the principal terms under discussion for a proposed patent license between [Licensor] and [Licensee]. Except as expressly provided in Section 11, this term sheet is non-binding and is intended only to facilitate further discussion. Either party may terminate discussions at any time. [Establishes non-binding status up front and names the parties—the two things term-sheet disputes most often turn on.]

1. Licensed Patents. Licensor will grant a license under the following patents and any continuations, continuations-in-part, divisionals, reissues, reexamination certificates, and foreign counterparts: U.S. Patent No. [Number], "[Title]," issued [Date]; [additional patents]. [Pin down exactly which patents, and how the patent family and future filings are treated. Vague patent definitions are litigation seeds.]

2. License Grant. Licensor will grant Licensee a [exclusive / sole / non-exclusive] license, under the Licensed Patents, to make, have made, use, sell, offer to sell, and import Licensed Products in the Field within the Territory. "Field" means [field of use, or "all fields"]; "Territory" means [geographic scope]; "Licensed Products" means [description]. [Choose exclusive/sole/non-exclusive deliberately. Confirm whether "have made" rights are granted or withheld—default is granted (CoreBrace). Make Field and Territory unambiguous.]

3. Improvements. [Licensor's improvements to the Licensed Patents during the Term are [included / available by option].] [Licensee grants Licensor a [non-exclusive, field-limited] license to Licensee's improvements.] [Address improvements explicitly; calibrate any grant-back for antitrust exposure.]

4. Financial Terms. Upfront Payment: $[Amount] on execution of the definitive agreement. Running Royalty: [X]% of Net Sales of Licensed Products [or $[Y] per unit]. Minimum Annual Royalty: $[Amount] beginning Year [X], creditable against running royalties. Milestone Payments: $[Amount] upon [event]. "Net Sales" means gross amounts invoiced less [returns, allowances, trade discounts, freight, and specified taxes]. [Define the royalty base with apportionment in mind—tie it to the invention's footprint, not a bundled product price. Define "Net Sales" precisely; every undefined deduction is a future dispute.]

5. Sublicensing. Licensee [shall / shall not] have the right to grant sublicenses. [If permitted: subject to Licensor's prior written consent, not to be unreasonably withheld; Licensee shall pay Licensor [X]% of sublicense revenue.]

6. Diligence. Licensee shall use commercially reasonable efforts to commercialize Licensed Products, satisfied by [payment of the Minimum Annual Royalty / achievement of the milestones in the attached commercialization plan]. [Prefer objective diligence benchmarks over a bare best-efforts clause.]

7. Term and Termination. The license continues for the life of the last-to-expire Licensed Patent unless earlier terminated. Either party may terminate for uncured material breach after [60] days' written notice. Licensor may terminate for failure to meet Minimum Annual Royalties or milestones. [Royalties cease on expiration of the Licensed Patents; any post-expiration payments are solely for the separately licensed Know-How.] [Honor Brulotte/Kimble: no patent royalties after expiration. If payments continue, tie them to know-how or other independent consideration, and say so.]

8. Reporting and Audit. Quarterly royalty reports within [45] days of each quarter's close. Licensor may audit Licensee's relevant records on [30] days' notice, no more than once per year, at Licensor's expense—provided that if an audit reveals underpayment exceeding [5]%, Licensee shall bear the audit cost and pay the shortfall with interest.

9. Patent Marking. Licensee shall mark Licensed Products in accordance with 35 U.S.C. § 287. [Failure to mark can forfeit pre-notice damages; put the obligation on the party making the products.]

10. Representations and Warranties. Licensor represents that it owns the Licensed Patents and has authority to grant this license. The license is otherwise granted "AS IS," without warranty of validity, enforceability, scope, or non-infringement of third-party rights. [Licensors represent ownership and authority and disclaim validity/FTO warranties—the market norm.]

11. Binding Provisions; Confidentiality; Governing Law. Section 11 and the confidentiality and exclusive-negotiation undertakings in [Annex A] are binding; all other provisions are non-binding and subject to a definitive agreement. This term sheet is governed by the laws of [State].

12. Definitive Agreement. The parties will negotiate in good faith to execute a definitive agreement within [60] days incorporating these terms and customary provisions.

ACKNOWLEDGED: [signature blocks]

From Term Sheet to Definitive Agreement

The term sheet captures intent; the definitive agreement converts intent into binding, litigable obligation—and the conversion is where the real drafting happens. Concise term-sheet phrases expand into operative language, standard provisions get added, and ambiguities that everyone glossed over surface and demand resolution.

The grant clause gets interrogated: does "make" include having products made by third parties (it does by default—CoreBrace)? Do licensed methods include testing and quality control? How exactly are each side's improvements handled? Payment provisions demand precision the term sheet didn't: how is the royalty calculated to the penny, which deductions reach net sales, how are returns, rebates, bundled sales, and affiliate sales handled? Imprecision here is the single most common source of license disputes. Representations, warranties, and indemnities get their survival periods, caps, baskets, and carve-outs negotiated. And the "boilerplate"—assignment and change-of-control, amendment, waiver, severability, integration, notice, governing law, dispute resolution—is not interchangeable filler; a poorly chosen assignment clause can let a licensee transfer your technology to your worst competitor in a corporate reshuffle. The drafting typically runs from a first draft (often the licensor's) through markups and iterative narrowing, with the gnarliest open issues escalated to the business principals who can actually trade them.

After Signing: Managing the Relationship

Signing starts the relationship; it does not end the work. For the licensor, ongoing management means tracking royalty reports and payments, exercising audit rights periodically (a never-audited licensee learns it can underreport), monitoring an exclusive licensee's commercialization against its diligence obligations, maintaining the licensed patents (a lapsed maintenance fee kills the whole revenue stream), enforcing the patents against unlicensed infringers (an unenforced patent is a worthless license, because licensees ask why they should pay for what others take for free), and tracking expirations. For the licensee, it means systems to track covered sales and calculate royalties accurately, timely and complete reporting, compliance with diligence and minimums, marking, monitoring patent status, protecting licensed know-how, and managing any sublicenses.

When disputes arise—over royalty math, alleged breach, validity, or changed circumstances—they run through the agreement's dispute-resolution ladder, usually escalating from business discussion to mediation to arbitration or litigation. And because long licenses outlive the assumptions they were built on, amendments become necessary as markets, technology, and corporate structures shift. Amendments require mutual agreement, which is one more reason the soft stuff—a constructive working relationship—has hard value.

Special Contexts

The fundamentals above apply broadly, but a few settings carry their own rules.

University and research-institution licensing runs on a distinct track. The Bayh-Dole Act (35 U.S.C. §§ 200–212) governs inventions made with federal funding, letting universities and other contractors elect to retain title subject to obligations—disclosure to the funding agency, a preference for U.S. manufacturing, a preference for small businesses and nonprofits in exclusive licensing, and the government's reserved "march-in" rights (§ 203) to compel licensing in defined circumstances. March-in has become a genuine policy battlefield. No federal agency has ever actually exercised march-in authority. In March 2023, the NIH declined a petition to march in on the prostate-cancer drug Xtandi, reasoning the drug was already widely available. In December 2023, NIST and an interagency working group released a draft framework that, for the first time, floated treating a product's price as a possible march-in consideration—drawing fierce opposition from universities, biopharma, and many patent scholars (who argued the statute does not authorize price-based march-in) and support from others. The draft was never finalized; price-based march-in remains unimplemented as of this writing. The takeaway for anyone licensing university-derived IP: the deal carries compliance and political dimensions a purely private deal does not, and university tech-transfer offices bring institutional missions and approval chains that shape every negotiation (AUTM publishes benchmark data worth consulting).

Cross-licensing—where two parties each license patents to the other—raises its own structural questions: balancing payments when the portfolios are unequal, grant-back terms, MFN clauses, and, crucially, antitrust scrutiny when the cross-licensing parties are competitors. Patent pools (where many owners pool patents for one-stop licensing) raise the same concerns at scale and are analyzed under the DOJ/FTC IP licensing guidelines.

Standard-essential patents (SEPs) are their own world. Once a patent becomes essential to practice an industry standard and the owner has pledged to license on fair, reasonable, and non-discriminatory (FRAND/RAND) terms, the ordinary freedom of a patentee shrinks dramatically: the owner generally cannot refuse to license and cannot demand whatever the market will bear. Notably, many of the Georgia-Pacific factors simply do not apply to SEPs, because a FRAND royalty must strip out the value the patent gained from being adopted into the standard as opposed to its intrinsic technical merit (Ericsson, Inc. v. D-Link Sys., Inc., 773 F.3d 1201, 1230–35 (Fed. Cir. 2014)). The whole regime—FRAND royalty methodology, the fights over injunctions against willing licensees, the global rate-setting litigation—is its own discipline, which we cover in standard-essential patents and FRAND licensing in 5G and IoT.

Corporate transactions—mergers, acquisitions, spin-offs—turn existing licenses into diligence items and drafting traps. Change-of-control and anti-assignment clauses in a license can block or trigger consent rights in a deal, and a restrictive license buried in a target's files can quietly subtract from transaction value. And frontier technologies create new uncertainty: patents on AI-related and other emerging inventions may carry uncertain scope and validity that complicate every step from valuation to structuring—see our discussion of AI-generated inventions and who owns what the machine creates. Practitioners doing software-centric deals will also want our guidance on drafting software license agreements.

Frequently Asked Questions

Can I keep collecting royalties after my patent expires? Not for the patent itself. Brulotte v. Thys and Kimble v. Marvel make post-expiration patent royalties unenforceable. You can structure payments that continue past expiration if they are genuinely for something else of independent value—licensed know-how, trade secrets, ongoing services—and the agreement says so clearly (Aronson v. Quick Point Pencil). Tie a hybrid license's surviving royalty to its non-patent component explicitly.

My licensee is now arguing my patent is invalid. Can it do that? Yes. Lear v. Adkins abolished licensee estoppel, and MedImmune lets a licensee challenge validity without even breaching the license or stopping royalty payments. You cannot contractually forbid the challenge outright, but you can raise its cost with step-up royalties, fee-shifting, and termination triggers.

Exclusive or non-exclusive—how do I choose? Exclusive when one capable partner will invest heavily and needs protection against competition (price it at a premium and protect yourself with minimums, milestones, and termination rights). Non-exclusive when the technology is broadly applicable, you want reach and diversified revenue, and no single licensee needs to be the only player. Consider a sole license, or field/geographic/temporal hybrids, when neither pure form fits.

What royalty rate is "normal"? It depends entirely on industry, the patent's strength, exclusivity, and the field—rough ballparks run from under 1% to mid-teens. Resist anchoring on a table; derive the rate from the Georgia-Pacific analysis applied to your facts, and validate it against real comparable licenses.

Should the royalty be a percentage of the whole product price? Usually not, if the product has unpatented components. Apportionment law (VirnetX, LaserDynamics, Finjan) requires the royalty to track the patented feature's contribution. Build the base on the smallest salable unit that captures the invention, or use a per-unit rate, rather than the entire market value of a bundled product.

Do I really need an audit clause if I trust the licensee? Yes. A running royalty you cannot verify is a number you have to take on faith, and even honest licensees make accounting errors that run in their favor. A standard clause—annual audit, licensor pays unless underpayment exceeds about 5%—costs nothing to include and is your only real enforcement of the royalty.

Is a term sheet binding? Most are deliberately non-binding as to deal terms, but specific provisions (confidentiality, exclusivity during negotiation, governing law, cost allocation) are usually meant to bind. The fix is simple and essential: state expressly which provisions bind and which do not.

Related Articles

Conclusion

Patent licensing is the art of turning a right to exclude into a stream of revenue without ever building a factory—and like most arts, it rewards craft and punishes carelessness. The craft is in the sequence this guide has traced: an honest assessment of whether the patent is worth licensing at all, a triangulated valuation that yields a defensible range rather than a wishful number, a target list of licensees who need the technology and can pay, a structure that matches the right grant to the right partner, a royalty architecture that allocates risk sensibly, and documentation precise enough to survive both prosperity and dispute. The carelessness is in the doctrinal landmines—Brulotte's ban on post-expiration royalties, Lear's licensee challenge right, exhaustion, misuse, the marking trap—that will quietly void a beautifully negotiated deal for a drafter who doesn't see them coming.

The deepest point is the one that is easiest to forget under the pressure of a negotiation: the best license is not the one that squeezes the most out of an unwilling counterparty, and it is certainly not the one that undervalues important technology to close fast. It is the one that creates genuine value on both sides—aligning incentives, allocating risk where each party can best bear it, and supporting a relationship productive enough to weather the amendments that long licenses inevitably need. That is what Helix Materials is after: not a one-time payday, but a durable structure that turns a clever bit of chemistry into years of revenue. Getting there combines legal precision with commercial judgment, which is to say it combines knowing the rules with knowing what the deal is actually for.

This article is educational and not legal advice. Patent licensing decisions turn on specific facts, and royalty benchmarks, agency guidance, and case law evolve—confirm current authority and consult qualified counsel before relying on anything described here.

Selected Authorities

Statutes: Patent Act, 35 U.S.C. §§ 154 (term), 271 (infringement; § 271(d) misuse), 284 (damages; reasonable royalty), 287 (marking); Bayh-Dole Act, 35 U.S.C. §§ 200–212 (including § 203 march-in rights); Bankruptcy Code, 11 U.S.C. § 365(n) (IP licenses in bankruptcy).

Supreme Court: Brulotte v. Thys Co., 379 U.S. 29 (1964) (no post-expiration patent royalties); Kimble v. Marvel Entertainment, LLC, 576 U.S. 446 (2015) (declining to overrule Brulotte); Lear, Inc. v. Adkins, 395 U.S. 653 (1969) (abolishing licensee estoppel); MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007) (licensee may challenge validity without breach); Aronson v. Quick Point Pencil Co., 440 U.S. 257 (1979) (royalties for know-how/idea may survive); Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008) (patent exhaustion); Impression Products, Inc. v. Lexmark Int'l, Inc., 581 U.S. 360 (2017) (exhaustion on restricted and foreign sales); Illinois Tool Works, Inc. v. Independent Ink, Inc., 547 U.S. 28 (2006) (no presumption of market power for tying).

Federal Circuit: Uniloc USA, Inc. v. Microsoft Corp., 632 F.3d 1292 (Fed. Cir. 2011) (rejecting 25% rule); Lucent Techs., Inc. v. Gateway, Inc., 580 F.3d 1301 (Fed. Cir. 2009) (hypothetical negotiation; lump-sum/running-royalty trade-offs); ResQNet.com, Inc. v. Lansa, Inc., 594 F.3d 860 (Fed. Cir. 2010) (comparable-license requirements); VirnetX, Inc. v. Cisco Sys., Inc., 767 F.3d 1308 (Fed. Cir. 2014); LaserDynamics, Inc. v. Quanta Computer, Inc., 694 F.3d 51 (Fed. Cir. 2012); Finjan, Inc. v. Blue Coat Sys., Inc., 879 F.3d 1299 (Fed. Cir. 2018); Commonwealth Sci. & Indus. Research Org. v. Cisco Sys., Inc., 809 F.3d 1295 (Fed. Cir. 2015) (apportionment, EMVR, SSPPU); Ericsson, Inc. v. D-Link Sys., Inc., 773 F.3d 1201 (Fed. Cir. 2014) (apportionment; FRAND/Georgia-Pacific); CoreBrace LLC v. Star Seismic LLC, 566 F.3d 1069 (Fed. Cir. 2009) (have-made rights); Am. Med. Sys., Inc. v. Med. Eng'g Corp., 6 F.3d 1523 (Fed. Cir. 1993) (marking).

Other: Georgia-Pacific Corp. v. U.S. Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970), modified, 446 F.2d 295 (2d Cir. 1971) (fifteen reasonable-royalty factors).

Agency materials & developments: NIST/Interagency Working Group, Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Dec. 2023; not finalized); NIH decision declining march-in on Xtandi (Mar. 2023); DOJ/FTC Antitrust Guidelines for the Licensing of Intellectual Property (2017).

Secondary sources: Licensing Executives Society (LES); Association of University Technology Managers (AUTM); WIPO technology-transfer resources; royalty-rate databases (ktMINE, RoyaltySource). Benchmarks and guidance evolve; verify before relying.